Physician profile
Logan N Walker
NPI 1821727090
$18,394.44
in general payments reported to CMS, 2019-2025
37 companies · $7,941 in 2025
The $7,941 reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $328 · 2022: $2,236 · 2023: $2,811 · 2024: $5,078 · 2025: $7,941.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,110 · Travel and Lodging: $3,669 · Honoraria: $3,240 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $800 · Education: $11.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,110.42 |
| Travel and Lodging | $3,668.94 |
| Honoraria | $3,240.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $800.00 |
| Education | $11.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $6,986.66 | 2022-2025 | Korlym |
| Tandem Diabetes Care, INC. | $2,190.64 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Medtronic, INC. | $2,064.67 | 2022-2025 | Minimed 780g |
| Bayer Healthcare Pharmaceuticals INC. | $1,477.20 | 2021-2025 | |
| Lilly USA, LLC | $1,134.97 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Beta Bionics, INC. | $821.18 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Novo Nordisk INC | $714.50 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Sanofi-Aventis U.S. LLC | $429.01 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $424.69 | 2022-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $299.14 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $251.01 | 2023-2025 | Gvoke Hypopen, Recorlev |
| Chiesi USA, INC. | $209.62 | 2024-2025 | Mycapssa, Myalept, Juxtapid |
| Kyowa Kirin, INC. | $160.38 | 2023 | Crysvita |
| Abbvie INC. | $159.41 | 2022-2024 | |
| Amgen INC. | $157.28 | 2024-2025 | Evenity, Prolia |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Logan Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.